Pharsight

Drugs that contain Fedratinib Hydrochloride

1. Inrebic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7825246 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(2 years from now)

US7528143 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Nov, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 IMPACT Use of bi-aryl meta-pyrimidine inhibitors of kinases
Jun, 2028

(4 years from now)

US10391094 IMPACT Compositions and methods for treating myelofibrosis
Jun, 2032

(8 years from now)

US11400092 IMPACT Methods of treating myeloproliferative disorders
Sep, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-259) Aug 16, 2026
New Chemical Entity Exclusivity(NCE) Aug 16, 2024

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...

Dosage: CAPSULE;ORAL

More Information on Dosage

INREBIC family patents

Family Patents